Lensar, a femtosecond laser technology provider, has obtained 510(k) approval from the US Food and Drug Administration (FDA) for a suite of five new application technologies integrated in its Lensar Laser System.


With the five new application upgrades, the Lensar Laser System with Streamline will automate several surgical procedure planning and execution elements.

The new application upgrades include wireless integration with the Cassini corneal shape analyzer, iris registration, cataract density imaging, customized fragmentation patterns and arcuate incision planning.

Lensar CEO Nicholas Curtis said: "The addition of the Streamline advanced technology suite solidifies our Lensar Laser System as the femtosecond platform of choice for today’s refractive cataract surgeon.

"The five distinct upgrades to the platform include innovative integration of functions unique to the Lensar Laser System that, for the first time, allow surgeons to fully automate and customize critical planning and execution steps of refractive cataract surgery."

The Cassini corneal shape analyzer allows the wireless transfer of data from preoperative corneal measurements to the Lensar Laser System, while arcuate incision planning helps surgeons to retain their plan preferences for later use and increasing surgical operating room efficiency.

According to the company, cataract density imaging allows the surgeon to automatically isolate fragmentation to the nucleus.

The company will showcase the Lensar Laser System with Streamline at the American Society of Cataract and Refractive Surgery Annual Meeting, which is being held from 18 to 20 April.

Image: FDA has granted approval for the Lensar Laser System with five new performance application upgrades. Photo: courtesy of Business Wire.